WAVE Life Sciences (NASDAQ:WVE) Insider Chris Francis Sells 1,883 Shares

WAVE Life Sciences Ltd. (NASDAQ:WVE) insider Chris Francis sold 1,883 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $13.45, for a total value of $25,326.35. Following the sale, the insider owned 61,867 shares in the company, valued at approximately $832,111.15. This represents a 2.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Chris Francis also recently made the following trade(s):

• On Friday, January 2nd, Chris Francis sold 9,375 shares of WAVE Life Sciences stock. The shares were sold at an average price of $16.03, for a total transaction of $150,281.25.
• On Monday, December 8th, Chris Francis sold 441,031 shares of WAVE Life Sciences stock. The shares were sold at an average price of $14.57, for a total transaction of $6,425,821.67.

WAVE Life Sciences Price Performance

NASDAQ WVE opened at $13.27 on Thursday. The company’s 50 day simple moving average is $14.99 and its two-hundred day simple moving average is $10.38. WAVE Life Sciences Ltd. has a 1 year low of $5.28 and a 1 year high of $21.73. The stock has a market capitalization of $2.22 billion, a PE ratio of -17.69 and a beta of -1.78.

WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.02). The firm had revenue of $7.61 million during the quarter, compared to the consensus estimate of $9.85 million. WAVE Life Sciences had a negative return on equity of 75.61% and a negative net margin of 111.64%. On average, research analysts anticipate that WAVE Life Sciences Ltd. will post -1.14 EPS for the current year.

Institutional Trading of WAVE Life Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nuveen LLC increased its position in WAVE Life Sciences by 33.4% during the 4th quarter. Nuveen LLC now owns 332,735 shares of the company’s stock valued at $5,656,000 after purchasing an additional 83,266 shares during the period. Primecap Management Co. CA increased its position in shares of WAVE Life Sciences by 115.7% during the fourth quarter. Primecap Management Co. CA now owns 4,095,282 shares of the company’s stock valued at $69,620,000 after buying an additional 2,196,632 shares during the period. Deutsche Bank AG increased its position in shares of WAVE Life Sciences by 1.5% during the fourth quarter. Deutsche Bank AG now owns 95,706 shares of the company’s stock valued at $1,627,000 after buying an additional 1,441 shares during the period. JPMorgan Chase & Co. raised its stake in WAVE Life Sciences by 3.8% in the fourth quarter. JPMorgan Chase & Co. now owns 892,886 shares of the company’s stock worth $15,179,000 after buying an additional 32,745 shares in the last quarter. Finally, WINTON GROUP Ltd purchased a new stake in WAVE Life Sciences in the fourth quarter worth about $250,000. Hedge funds and other institutional investors own 89.73% of the company’s stock.

Wall Street Analyst Weigh In

WVE has been the topic of a number of recent analyst reports. Oppenheimer raised their target price on shares of WAVE Life Sciences from $24.00 to $32.00 and gave the company an “outperform” rating in a research note on Tuesday, December 16th. Royal Bank Of Canada raised shares of WAVE Life Sciences from a “sector perform” rating to an “outperform” rating and increased their price target for the stock from $9.00 to $27.00 in a report on Monday, December 8th. Cantor Fitzgerald lifted their price target on shares of WAVE Life Sciences from $34.00 to $41.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Wedbush upped their price objective on shares of WAVE Life Sciences from $20.00 to $33.00 and gave the company an “outperform” rating in a research note on Friday, December 12th. Finally, Raymond James Financial reissued an “outperform” rating and issued a $21.00 price target on shares of WAVE Life Sciences in a research note on Monday, December 8th. Fourteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, WAVE Life Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.69.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.